Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2. The median age of the patients was 19 years. Patients received oral busulfan 4 mg/kg/day for 2 days; i.v. cyclophosphamide 350 mg/ m 2 /day for 3 days; and i.v. fludarabine 30 mg/m 2 /day for 3 days. Oral cyclosporin A 4 mg/kg was started and methotrexate 5 mg/m 2 was delivered on days 1, 3, 5 and 11. The median CD34 þ cell dose received was 5.0 Â 10 6 / kg. The medium time to achieve a granulocyte count above 0.5 Â 10 9 /l was 14 days. Thirteen patients were alive 30-1050 days after the HSCT. The 3-year overall survival rate was 30%. Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD. Thirty patients died between days 47 and 1050 after the HSCT, most of them (70%) because of an ALL relapse. One hundred-day mortality was 15%, whereas transplant-related mortality was 21%. These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
Introduction
ALL accounts for approximately 20% of all adult acute leukemias. Despite an optimal use of antileukemic agents, reported cure rates do not exceed 40% in high-risk ALL adult patients. [1] [2] [3] Many clinical and biological variables have been proposed as risk factors for leukemia relapse in these patients. Both age and leukocyte count at diagnosis and host pharmacodynamics and genetic abnormalities of leukemia cells have been associated with a high relapse risk, but it is clear that the response to therapy, which reflects the genetics of leukemia cells and the pharmacodynamics and pharmacogenetics of the host, has greater prognostic strength than does any other biologic or clinical feature tested to date. 4 On the other hand, the poor results obtained through conventional chemotherapy have encouraged the use of other therapeutic strategies to improve the prognosis of high-risk ALL patients, including allogeneic hematopoietic stem cell transplantation (HSCT) in the earliest phase of the disease. 5 There are three valid premises related to HSCT: a cure may be attributed to a graftversus-tumor effect; donor lymphocyte infusions can induce sustained CRs; and neoplastic diseases cannot always be eradicated even by the most intensive pretransplantation therapies. 6 While in standard-risk ALL patients the initial objective of HSCT is to eliminate the residual leukemia cells using high doses of chemo-radiotherapy, non-myeloablative conditioning HSCT focuses on eradicating the leukemia clone by taking advantage of the alloimmune effect from the transplanted cells in addition to tumor cytoreduction, thereby limiting the toxicity related to radiation and highdose chemotherapy exposure. The antileukemic effect of the graft-versus-host reaction has been clearly recognized in patients with chronic granulocytic leukemia, and to a lesser extent in those with AML, but the allogeneic effect in ALL patients beyond the first remission is weaker than that in myeloid malignancies. Since information is scarce regarding the use of reduced-intensity conditioning in HSCT for ALL patients, we prospectively evaluated the therapeutic value of non-myeloablative conditioning allogeneic HSCT in 43 ALL patients in second remission. The non-ablative conditioning was selected because of its affordability in our country.
Materials and methods

Patients and donors
Patients allografted in the Centro de Hematologı´a y Medicina Interna de Puebla (Puebla, Me´xico) and the Hospital Universitario de Nuevo Leo´n (Monterrey, Me´xico) were prospectively accrued in the study. All patients were in their second hematological remission and had a Karnofsky score of 100% when the procedure was performed. No patients had relapsed off therapy before the transplant; all had experienced the relapse during the treatment. The donor was an HLA-identical (6/6) sibling in all instances. Institutional review board approval and written consent were obtained from all the individuals.
HSC mobilization and apheresis G-CSF (10 mg/kg/day) was delivered to the sibling donors on day À5 to þ 1. One or two apheresis procedures were scheduled to be carried out on days 0 and þ 1, depending on the CD34 þ cells obtained, by means of a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA), a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA) and an AMICUS (Baxter Healthcare, Deerfield, IL, USA) or a COBE Spectra (Gambro, Lakewood, CO, USA) using the Spin-Nebraska protocol. 7 The purpose of the collection was to process 5000-7000 ml of blood/m 2 in each apheresis procedure, 8, 9 to obtain at least 5 Â 10 8 mononuclear cells and/or 2 Â 10 6 viable CD34 cells/kg of the recipient's weight.
Conditioning and grafting
All patients received a low-intensity conditioning regimen based on oral busulfan 4 mg/kg delivered over 2 days (À6 and À5), i.v. cyclophosphamide 350 mg/m 2 on days À4, À3 and À2 and i.v. fludarabine 30 mg/m 2 on days À4, À3 and À2. Oral CyA 4 mg/kg was started on day À1 and i.v. methotrexate 5 mg/m 2 was delivered on days þ 1, þ 3, þ 5 and þ 11. Oral CyA was continued through day 180, with adjustments to obtain serum CyA levels between 150 and 275 ng/ml; it was then tapered over 30-60 days. If GVHD data were present, the CyA tapering was done over longer periods. Ondansetron (8 mg i.v. after i.v. chemotherapy), oral ciprofloxacin and fluconazole were used in all patients until more than 500 granulocytes/ml were present. In 35 patients (81%), HSCT was performed in an outpatient setting. The products of the PBSC apheresis were reinfused on days 0 to þ 1.
Apheresis product studies Enumeration of the total white blood, mononuclear (MNC) and CD34-positive cells was done by flow cytometry 10, 11 in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using the anti-CD34 monoclonal antibody HPCA-2 11 (Becton Dickinson, San Jose´, CA, USA). No purging procedures were performed.
Molecular biology studies
In cases of a sex mismatch, a fluorescent in situ hybridization technique was performed to display the X and Y chromosomes; 12 in cases of an ABO system mismatch, a flow-cytometry-based approach was used, whereas in the absence of the previously mentioned mismatches, multi-lineage polymorphic markers (STRs) 13 were analyzed. The BCR/ABL-specific transcripts were detected by non-quantitative multiplex RT-PCR. Details of this method have been published in the past.
14 Sensitivity for the detection of BCR/ABL transcripts is about 10 À5 as has been determined by previous dilution experiments with K562 cells. The molecular biology studies were performed at diagnosis, at 30 days after the allograft and every 3-6 months afterwards. Survival was calculated according to the Kaplan and Meier method.
Results
Forty-three ALL individuals were allografted. Seventeen were children under 16 years of age; the median age was 19 years (range 1-55). Nineteen were females. All patients were diagnosed with B-lineage ALL in CR2 and two were found to display the BCR/ABL fusion transcript. Median time from diagnosis to the allograft was 570 days (range 60-3480). Patients received a median of 5.0 Â 10 6 /kg CD34 ( þ ) cells, using one or two apheresis procedures. Median time to achieve a granulocyte count above 0.5 Â 10 9 /l was 14 days, range 0-25. Median time to achieve a platelet count above 20 Â 10 9 /l was also 15 days, range 0-109. Acute GVHD was defined as that occurring before day 100; 10 patients developed acute GVHD (23%), 1 of them of grade IV and 9 of grades 1 or 2, whereas 8 patients (18.6%) developed chronic GVHD. Twenty-eight patients (65%) had a leukemic relapse after the transplant. Thirteen patients were alive 30-1050 days (median 235) after the transplant. The overall 3-year survival was 31%, whereas median survival was 235 days. Figure 1 depicts these data. Disease-free survival (DFS) was 5 months. Figure 2 shows the actuarial probabilities of DFS. Thirty patients (69%) died between 47 and 1050 days after the HSCT, most of them of a relapse (70%). The 100-day mortality was 15%, whereas the transplant-related mortality was 21% (GVHD in five patients, infection in three patients and central nervous system hemorrhage in one patient). There were no significant differences in results between adult and pediatric groups. 
Discussion
Individuals with acute lymphoblastic leukemia who are given remission-induction chemotherapy achieve CR rates of about 85%; however, in adult patients, it is clear that only 30-40% will experience long-term DFS. 5 Currently, relapse remains the main obstacle to improve the outcome in adult ALL patients. Given the poor results observed in second or subsequent remission ALL patients, many centers choose to use myeloablative chemoradiotherapy and HSCT. An emergent therapeutic option is a nonmyeloablative conditioning HSCT, which attempts to eradicate leukemia through the alloimmune effect from the transplanted cells, thereby limiting radiation and chemotherapy exposure. There are not enough data evaluating non-myeloablative conditioning regimens for allogeneic HSCT in second remission ALL, but using a myeloablative regimen seems to have limited results. Doney et al. reported the results of 182 adult patients with ALL treated with an allogeneic BMT in CR1 or CR2 using a myeloablative conditioning. They showed that patients who underwent transplantation in CR1 had significantly (Po0.001) better 5-year DFS (43%) than those who underwent transplantation in CR2 (23%) or in relapse (9%). 15 Recent data suggest that BMT allografting in adults with ALL in CR1 may be the treatment of choice, even in patients with standard risk. 16 In pediatric ALL patients, improvement in results using frontline chemotherapy has been satisfactory; therefore transplantation is usually not indicated in CR1, whereas in CR2, allogeneic HSCT has demonstrated higher levels of improvement in the DFS than continued chemotherapy. 17, 18 Other studies 19, 20 show that long-term DFS for high-risk ALL children who received an allogeneic HSCT in CR1 ranges between 16 and 52%. Seventeen pediatric patients were included in our study, five of them (30%) were alive at the publication of this article in a sustained CR, while 67% died from leukemic relapse. These results are similar to those obtained with conventional allografting.
The conditioning regimen used in our study was able to induce complete donor chimerism in all patients. It is important to note that before starting the conditioning therapy, all patients had a Karnofsky performance status of 100% and significant chemotherapy-related toxicity was not observed. Given these conditions, 35 procedures (81%) could be performed in an outpatient setting. 21 The hematopoietic recovery time (day þ 15) was similar to that reported in a previous study using the same conditioning regimen in chronic myelogenous leukemia. 22 Acute GVHD may lower the relapse rate in ALL in both first and second remission. 23 Ringden et al. 24 assessed the impact of acute and chronic GVHD in ALL patients allografted in CR1 or CR2, showing a significant decrease in the relapse rate for both groups, but, at the same time, a significant treatmentrelated mortality according to the grade of acute GVHD. In our study, the incidence of relapse in patients with GVHD (66%) was similar to that of those without GVHD (61%). The first cause of death in our patients was relapse (70%) in spite of demonstrating full or mixed chimerism (range: 40-100%). Other causes of death were GVHD (17%), infection (10%) and a central nervous system hemorrhage in one patient. At a 1050-day follow-up, 30 patients (69%) were dead and 13 (31%) were in CR. The overall survival rate observed in this study is comparable to other studies of relapsed ALL patients transplanted using a myeloablative conditioning: Doney et al. 15 reported a 24% DFS at 5 years for ALL patients in second or subsequent remissions who received allogeneic hematopoietic cell transplantation.
Our results in allografting patients with ALL in a second remission are clearly inferior to those obtained using the same allografting method in CML 22 and in AML. 25 In CML, the overall 830-day survival was 92%, 22 whereas in AML, the overall 860-day survival was 66%. Figure 3 graphs this information. A possible explanation for these differences, as mentioned previously, is the poor susceptibility to the graft-versus-leukemia effect of ALL cells as compared with that of other hematological malignancies. [26] [27] [28] We conclude that HSCT with non-myeloablative conditioning for ALL patients in second remission can induce stable chimerism and moreover, that the outcome could be similar to more intensive and more toxic pre-transplant regimens. This allografting approach appears to be broadly applicable, given that the transplantations can be performed effectively in an outpatient setting with minimal toxicity and few supportive care requirements resulted in cost-lowering. 29 Prospective and innovative studies are needed in the field of transplantation for patients with relapsed ALL.
